Navigation Links
America's Biopharmaceutical Companies' Commitment to Research Remains Strong Despite Challenges
Date:4/11/2013

WASHINGTON, April 11, 2013 /PRNewswire-USNewswire/ -- Investment in research and development (R&D) by member companies of the Pharmaceutical Research and Manufacturers of America (PhRMA) remained strong at an estimated $48.5 billion in 2012, despite economic, scientific, and business challenges. These efforts are highlighted in PhRMA's 2013 Biopharmaceutical Research Industry Profile released today.

(Logo: http://photos.prnewswire.com/prnh/20091027/PHRMALOGO)

The 2012 R&D investment figures reflect the biopharmaceutical sector's continued standing as America's most research-intensive industry.  In 2012, PhRMA members invested nearly 21 percent of domestic sales into R&D.

"Investment in research is crucial to bringing new treatments to patients for our most challenging and costly diseases," said John J. Castellani , PhRMA president and CEO. "The U.S. biopharmaceutical sector – led by our member companies – is a major contributor to American innovation and to the domestic economy."

This commitment to research and development is reflected in the robust biopharmaceutical pipeline, which has a high proportion of potential first-in-class medicines and therapies targeting diseases with limited treatment options. According to a report released by PhRMA earlier this year, more than 5,400 medicines are in development globally, representing future opportunities for new, cutting-edge medicines to improve patient care and bring value to the U.S. health care system.

The biopharmaceutical industry's approach to R&D continues to evolve and adapt to scientific advancements, rising drug development costs and changing regulatory requirements.  Companies are increasingly focused on targeting some of the most complex diseases such as Alzheimer's, cancer and Parkinson's, and are identifying advances in technology to improve R&D productivity and efficiency.

In addition to conducting research in-house, biopharmaceutical companies increasingly support research through other arrangements such as corporate venture capital funds, licensing agreements with other companies, and public-private partnerships.  As the complexity of the science requires broader expertise, these collaborative efforts allow companies to diversify their portfolios and to access new technologies that can result in R&D efficiencies.

"The discovery and development of new treatments saves and improves patients' lives. Supporting continued innovation and a thriving biopharmaceutical research sector requires a long-term view, with policies and regulatory structures that are consistent, predictable and focused on patients' needs," concluded Castellani. 

The biopharmaceutical research sector supports nearly four million jobs in the U.S. and the overall impact of the sector on the domestic economy is $917 billion annually. Since 2000, PhRMA member companies alone have invested approximately $550 billion in research and development of new therapies for a wide range of diseases such as diabetes, heart disease and HIV/AIDS.

The 2012 R&D numbers reflect investment made by PhRMA's 31 members.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested nearly $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.

Find PhRMA Online:

For information on how innovative medicines save lives, visit: http://www.innovation.org 
For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org 
For information on ensuring the flow of medicines during public health emergencies, visit http://www.rxresponse.org


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DKMS Americas announces new branding initiative to increase donor registry numbers
2. Cochlear Americas Announces 2013 Graeme Clark and Anders Tjellstrom Scholarship Winners
3. Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region
4. Pharmalink Consulting Appoints Chief Operating Officer for the Americas
5. EvaluatePharma Names Debbie Paul CEO, Americas to Lead Growth in Key Region
6. Cochlear Americas Receives FDA Approval of the Worlds Thinnest, Full Length Electrode for Cochlear Implantation
7. DICOM Grid Selected as a Finalist for the 2012 Red Herring Top 100 Americas Award
8. Cochlear™ Americas Adds the Nucleus® Support App to its Mobile Service Offerings
9. First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals Lead Therapeutic Candidate for Treatment of Migraine, ALD403
10. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
11. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... SAN DIEGO and PALMA, ... Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical ... announced that the first patient has been enrolled ... of lead candidate, SNF472, for the treatment of ... haemodialysis (HD). Most ESRD patients, in ...
(Date:1/21/2017)... 20, 2017 Research and Markets has ... Market By Type of Test (Tumor, Clinical Chemistry, Microbiology, Esoteric), ... of Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS etc.), Forecast to 2022" ... ... healthcare services, market segments, especially clinical lab testing, which has ...
(Date:1/21/2017)... Jan 20, 2017 Research and Markets has ... & Trends - Technology, Route Of Administration, End User - Forecast ... ... poised to grow at a CAGR of around 7.8% over the ... This industry report analyzes the global markets for Advanced Drug ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... The American Academy of ... scientific development, healthcare training and clinical application of medical infrared imaging, has announced ... Certification Qualification Courses for Technicians, respectively. , For the first time the AAT ...
(Date:1/23/2017)... Switzerland (PRWEB) , ... January 23, 2017 , ... ... lab and production applications. However, choosing the right method is paramount to success. ... occur more often in situations where multiple persons use the same equipment. Rare ...
(Date:1/23/2017)... ... ... Old School Labs™, makers of the wildly popular all-natural sports supplements based ... its growing team of brand ambassadors. The Olympia top finisher and former Big 12 ... year was able to turn professional, participating in the 2013 NPC USA Championships in ...
(Date:1/23/2017)... ... ... a story of love and redemption, hope and uncertainty as a girl makes her ... Inn at the Mill” is the creation of published author, Lois Kulp, who was born ... Berks County on Crow Hill. The inn, the mill and "Post Yokel" are ...
(Date:1/23/2017)... ... ... “Life Under Blankets”: an entrancing story about one woman's travels through the ... creation of published author, Kimberly Mitchell, who earned her bachelor’s degree in English education ... a master’s degree in education in the field of curriculum and instruction. Kimberly’s passion ...
Breaking Medicine News(10 mins):